Mobocertinib – Uses, Dosage, Side Effects, Interaction

Mobocertinib is an inhibitor of EGFR that preferentially targets exon 20 insertion mutant variants. It is available as an oral capsule taken with or without food once daily. Mobocertinib can cause a concentration-dependent increase in QTc interval which may lead to life-threatening complications such as Torsades de Pointes. Patients with baseline risk factors for QTc prolongation should consider alternative medications or be monitored carefully throughout therapy. The use of concomitant QTc-prolonging medications should be avoided, as should concomitant inhibitors of CYP3A, as these may increase the concentration of mobocertinib and thus the risk of QTc-prolongation.

Use in Cancer

Mobocertinib succinate is approved to treat:

• Non-small cell lung cancer (NSCLC) is locally advanced or metastatic and got worse during or after platinum chemotherapy. It is used in adults whose cancer has certain EGFR gene mutations.

Mobocertinib succinate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit to these patients.

Mobocertinib succinate is also being studied in the treatment of other conditions.

Contraindications

• low amount of magnesium in the blood
• low amount of calcium in the blood
• low amount of potassium in the blood
• torsades de pointes, a type of abnormal heart rhythm
• prolonged QT interval on EKG
• chronic heart failure
• abnormal EKG with QT changes from birth
• pregnancy
• a patient who is producing milk and breastfeeding
• lung tissue problem

Dosage

Strengths: 40 mg

Non-Small Cell Lung Cancer

• 160 mg orally once a day
• Duration of therapy: Until disease progression or unacceptable toxicity

Renal Dose Adjustments

• Mild to moderate renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended.
• Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available
• Estimated GFR 30 to 89 mL/min/1.73 m2 by Modification of Diet in Renal Disease equation
• The recommended dosage has not been established for patients with severe renal dysfunction.

Liver Dose Adjustments

• Mild or moderate liver dysfunction: No adjustment is recommended.
• Severe liver dysfunction: Data not available
• Mild liver dysfunction: Total bilirubin up to the upper limit of normal (ULN) and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN (1 to 1.5 x ULN) and any AST
• Moderate liver dysfunction: Total bilirubin 1.5 to 3 x ULN and any AST
• Severe liver dysfunction: Total bilirubin greater than 3 x ULN and any AST
• The recommended dosage has not been established for patients with severe liver dysfunction.

Dose Adjustments

Dose reduction levels for adverse reactions:

• First dose reduction: 120 mg orally once a day
• Second dose reduction: 80 mg orally once a day

QTc Interval Prolongation and Torsades de Pointes

• Grade 2 (QTc interval 481 to 500 msec):
• First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the same dose.
• Recurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
• Grade 3 (QTc interval at least 501 msec or QTc interval increase of greater than 60 msec from baseline):
• First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
• Recurrence: This drug should be permanently discontinued.
• Grade 4 (torsades de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia): This drug should be permanently discontinued.

Interstitial Lung Disease (ILD)/Pneumonitis:

• Any grade: This drug should be withheld if ILD/pneumonitis is suspected; if ILD/pneumonitis is confirmed, this drug should be permanently discontinued.

Decreased Ejection Fraction or Heart Failure:

• Grade 2 decreased ejection fraction: This drug should be withheld until Grade 1 or lower or baseline.
• If recovered to baseline within 2 weeks: This drug should resume at the same dose or the next lower dose.
• If not recovered to baseline within 2 weeks: This drug should be permanently discontinued.
• At least Grade 2 heart failure or Grade 3 or 4 decreased ejection fraction: This drug should be permanently discontinued.

Diarrhea:

• Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
• Grade 4:
• First occurrence: This drug should be withheld until Grade 1 or lower; this drug should resume at the next lower dose.
• Recurrence: This drug should be permanently discontinued.

Other Adverse Reactions:

• Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
• Grade 4:
• First occurrence: This drug should be withheld until Grade 1 or lower.
• If recovery occurs within 2 weeks: This drug should resume at the next lower dose.
• If recovery does not occur within 2 weeks: This drug should be permanently discontinued.
• Recurrence: This drug should be permanently discontinued.
• Graded per National Cancer Institute Common Terminology Criteria for Adverse Events
• Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided.
• If coadministration cannot be avoided: The mobocertinib dose should be reduced by about 50% (i.e., from 160 to 80 mg, 120 to 40 mg, or 80 to 40 mg) and QTc interval should be monitored more frequently.
• After the moderate CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives: Mobocertinib should resume at the dose taken before starting the moderate CYP450 3A inhibitor.

Administration advice:

• Select patients with locally advanced/metastatic NSCLC for treatment with this drug based on the presence of EGFR exon 20 insertion mutations.
• For information on US FDA-approved tests: fda.gov/CompanionDiagnostics
• Administer with or without food, at the same time each day.
• Swallow capsules whole; do not open, chew, or dissolve the contents of the capsules.
• If a dose is vomited, do not administer an additional dose; administer the next dose as prescribed the following day.

Side Effects

The Most Common

• nausea
• vomiting
• mouth sores
• decreased appetite
• weight loss
• stomach pain
• heartburn
• rash
• dry skin or itching
• red, itchy, or irritated eyes
• blurry vision
• hair loss
• nail infection
• tiredness
• muscle or bone pain
• fatigue
• runny nose
• headache
• diarrhea
• cough
• fever
• shortness of breath
• chest pain
• swelling of your ankles and feet

More common

• Agitation
• bloating or swelling of the face, arms, hands, lower legs, or feet
• bloody eye
• blurred vision or blue-green halos seen around objects
• coma
• confusion
• decreased urine output
• depression
• diarrhea
• dizziness
• dry eyes
• fainting
• fast, pounding, or irregular heartbeat or pulse
• headache
• hostility
• irregular heartbeat recurrent
• irritability
• lethargy
• muscle twitching
• nausea
• nervousness
• palpitations
• pounding in the ears
• rapid weight gain
• redness, swelling, and/or itching of the eyelid
• seizures
• sensitivity of the eyes to light
• stupor
• swelling of the face, ankles, or hands
• tingling of the hands or feet
• unusual tiredness or weakness
• unusual weight gain or loss

Rare

• Chest pain or discomfort
• chills
• cough
• dilated neck veins
• fever
• a general feeling of discomfort or illness
• irregular breathing
• swelling of the face, fingers feet, or lower legs
• thickening of bronchial secretions
• trouble breathing
• Acid or sour stomach
• belching
• body aches or pain
• burning, numbness, tingling, or painful sensations
• cracked lips
• decreased appetite
• difficulty in moving
• ear congestion
• heartburn
• indigestion
• loosening of the fingernails
• loss or thinning of the hair
• loss of voice
• muscle or bone pain
• pain in the arms or legs
• rash
• redness or soreness around the fingernails
• sneezing
• sore throat
• sores, ulcers, or white spots on the lips, tongue, or inside the mouth
• stomach discomfort, upset, or pain
• stuffy or runny nose
• swelling or inflammation of the mouth
• tender, swollen glands in the neck
• trouble in swallowing
• unsteadiness or awkwardness
• voice changes
• vomiting
• weakness in the arms, hands, legs, or fee
• Redness, swelling, pain of the skin
• scaling of the skin on the hands and feet
• ulceration of the skin

Drug interaction

DRUG	INTERACTION
Abametapir	The serum concentration of Mobocertinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Mobocertinib can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be decreased when it is combined with Mobocertinib.
Acalabrutinib	The serum concentration of Acalabrutinib can be decreased when it is combined with Mobocertinib.
Acebutolol	The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Mobocertinib.
Acenocoumarol	The serum concentration of Acenocoumarol can be decreased when it is combined with Mobocertinib.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Mobocertinib.
Adalimumab	The metabolism of Mobocertinib can be increased when combined with Adalimumab.
Adenosine	The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mobocertinib.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Mobocertinib.
Alectinib	The serum concentration of Alectinib can be decreased when it is combined with Mobocertinib.
Alfentanil	The metabolism of Mobocertinib can be decreased when combined with Alfentanil.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mobocertinib.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Mobocertinib.
Alpelisib	The serum concentration of Alpelisib can be decreased when it is combined with Mobocertinib.
Alprazolam	The metabolism of Mobocertinib can be decreased when combined with Alprazolam.
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mobocertinib.
Ambrisentan	The metabolism of Mobocertinib can be decreased when combined with Ambrisentan.
Amifampridine	The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Mobocertinib.
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Mobocertinib.
Amiodarone	The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Mobocertinib.
Amisulpride	The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Mobocertinib.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Mobocertinib.
Amlodipine	The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Mobocertinib.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Mobocertinib.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Mobocertinib.
Amprenavir	The serum concentration of Mobocertinib can be increased when it is combined with Amprenavir.
Anagrelide	The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Mobocertinib.
Anakinra	The metabolism of Mobocertinib can be increased when combined with Anakinra.
Antazoline	The risk or severity of QTc prolongation can be increased when Antazoline is combined with Mobocertinib.
Apalutamide	The serum concentration of Mobocertinib can be decreased when it is combined with Apalutamide.
Apixaban	The metabolism of Mobocertinib can be decreased when combined with Apixaban.
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mobocertinib.
Apremilast	The metabolism of Mobocertinib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Mobocertinib can be decreased when combined with Aprepitant.
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Mobocertinib.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Mobocertinib.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Mobocertinib.
Armodafinil	The metabolism of Mobocertinib can be increased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Mobocertinib.
Artemether	The risk or severity of QTc prolongation can be increased when Artemether is combined with Mobocertinib.
Asenapine	The risk or severity of QTc prolongation can be increased when Asenapine is combined with Mobocertinib.
Astemizole	The risk or severity of QTc prolongation can be increased when Astemizole is combined with Mobocertinib.
Asunaprevir	The metabolism of Mobocertinib can be decreased when combined with Asunaprevir.
Atazanavir	The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Mobocertinib.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mobocertinib.
Atorvastatin	The metabolism of Mobocertinib can be decreased when combined with Atorvastatin.
Atropine	The risk or severity of QTc prolongation can be increased when Atropine is combined with Mobocertinib.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Mobocertinib.
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Mobocertinib.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Mobocertinib.
Azelastine	The metabolism of Mobocertinib can be decreased when combined with Azelastine.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Mobocertinib.
Beclomethasone	The metabolism of Mobocertinib can be increased when combined with Beclomethasone dipropionate.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Mobocertinib.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Mobocertinib.
Bepridil	The risk or severity of QTc prolongation can be increased when Bepridil is combined with Mobocertinib.
Berotralstat	The metabolism of Mobocertinib can be decreased when combined with Berotralstat.
Betamethasone	The metabolism of Mobocertinib can be increased when combined with Betamethasone.
Betamethasone	The metabolism of Mobocertinib can be increased when combined with Betamethasone phosphate.
Betaxolol	The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Mobocertinib.
Bicalutamide	The serum concentration of Bicalutamide can be decreased when it is combined with Mobocertinib.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Mobocertinib.
Bimekizumab	The metabolism of Mobocertinib can be increased when combined with Bimekizumab.
Boceprevir	The serum concentration of Mobocertinib can be increased when it is combined with Boceprevir.
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mobocertinib.
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Mobocertinib.
Brentuximab	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mobocertinib.
Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Mobocertinib.
Brigatinib	The serum concentration of Brigatinib can be decreased when it is combined with Mobocertinib.
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Mobocertinib.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Mobocertinib.
Budesonide	The metabolism of Mobocertinib can be increased when combined with Budesonide.
Buprenorphine	The metabolism of Mobocertinib can be decreased when combined with Buprenorphine.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Mobocertinib.
Buspirone	The metabolism of Mobocertinib can be decreased when combined with Buspirone.
Busulfan	The serum concentration of Busulfan can be decreased when it is combined with Mobocertinib.
Butriptyline	The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Mobocertinib.
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Mobocertinib.
Cabergoline	The serum concentration of Cabergoline can be decreased when it is combined with Mobocertinib.
Canakinumab	The metabolism of Mobocertinib can be increased when combined with Canakinumab.
Cannabidiol	The metabolism of Mobocertinib can be decreased when combined with Cannabidiol.
Carbamazepine	The serum concentration of Mobocertinib can be decreased when it is combined with Carbamazepine.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Mobocertinib.
Celiprolol	The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Mobocertinib.
Cenobamate	The serum concentration of Mobocertinib can be decreased when it is combined with Cenobamate.
Ceritinib	The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Mobocertinib.
Cerivastatin	The metabolism of Mobocertinib can be decreased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Mobocertinib can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Mobocertinib.
Chloramphenicol	The metabolism of Mobocertinib can be decreased when combined with Chloramphenicol.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Mobocertinib.
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Mobocertinib.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Mobocertinib.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Mobocertinib.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Mobocertinib.
Cilostazol	The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Mobocertinib.
Cimetidine	The metabolism of Mobocertinib can be decreased when combined with Cimetidine.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Mobocertinib.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Mobocertinib.

Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mobocertinib.
Cisapride	The risk or severity of QTc prolongation can be increased when Cisapride is combined with Mobocertinib.
Citalopram	The risk or severity of QTc prolongation can be increased when Citalopram is combined with Mobocertinib.
Clarithromycin	The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Mobocertinib.
Clemastine	The risk or severity of QTc prolongation can be increased when Clemastine is combined with Mobocertinib.
Clindamycin	The metabolism of Mobocertinib can be decreased when combined with Clindamycin.
Clobetasol	The metabolism of Mobocertinib can be increased when combined with Clobetasol propionate.
Clofazimine	The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Mobocertinib.
Clomipramine	The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Mobocertinib.
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Mobocertinib.
Clopidogrel	The metabolism of Mobocertinib can be decreased when combined with Clopidogrel.
Clozapine	The risk or severity of QTc prolongation can be increased when Clozapine is combined with Mobocertinib.
Cobicistat	The serum concentration of Mobocertinib can be increased when it is combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Mobocertinib.
Cocaine	The risk or severity of QTc prolongation can be increased when Cocaine is combined with Mobocertinib.
Conivaptan	The serum concentration of Mobocertinib can be increased when it is combined with Conivaptan.
Copanlisib	The serum concentration of Copanlisib can be decreased when it is combined with Mobocertinib.
Cortisone acetate	The metabolism of Mobocertinib can be increased when combined with Cortisone acetate.
Crizotinib	The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Mobocertinib.
Curcumin	The serum concentration of Mobocertinib can be increased when it is combined with Curcumin.
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Mobocertinib.
Cyclophosphamide	The serum concentration of Cyclophosphamide can be decreased when it is combined with Mobocertinib.
Cyclosporine	The serum concentration of Cyclosporine can be decreased when it is combined with Mobocertinib.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Mobocertinib.
Cyproterone acetate	The serum concentration of Cyproterone acetate can be decreased when it is combined with Mobocertinib.
Dabrafenib	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mobocertinib.
Daclatasvir	The metabolism of Mobocertinib can be decreased when combined with Daclatasvir.
Dacomitinib	The serum concentration of Dacomitinib can be decreased when it is combined with Mobocertinib.
Danazol	The serum concentration of Mobocertinib can be increased when it is combined with Danazol.
Dapsone	The metabolism of Mobocertinib can be decreased when combined with Dapsone.
Darunavir	The serum concentration of Mobocertinib can be increased when it is combined with Darunavir.
Dasatinib	The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mobocertinib.
Daunorubicin	The metabolism of Mobocertinib can be increased when combined with Daunorubicin.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mobocertinib.
Delafloxacin	The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Mobocertinib.
Delamanid	The risk or severity of QTc prolongation can be increased when Delamanid is combined with Mobocertinib.
Delavirdine	The serum concentration of Mobocertinib can be increased when it is combined with Delavirdine.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Mobocertinib.
Desipramine	The risk or severity of QTc prolongation can be increased when Desipramine is combined with Mobocertinib.
Desloratadine	The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Mobocertinib.
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Mobocertinib.
Desvenlafaxine	The metabolism of Mobocertinib can be decreased when combined with Desvenlafaxine.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Mobocertinib.
Dexamethasone	The serum concentration of Mobocertinib can be decreased when it is combined with Dexamethasone.
Dexamethasone	The metabolism of Mobocertinib can be increased when combined with Dexamethasone acetate.
Dexbrompheniram	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mobocertinib.
Dexchlorphenira	The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Mobocertinib.
Dextromethorphan	The metabolism of Mobocertinib can be decreased when combined with Dextromethorphan.
Diazepam	The metabolism of Mobocertinib can be decreased when combined with Diazepam.
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Mobocertinib.
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Mobocertinib.
Difluocortolone	The metabolism of Mobocertinib can be increased when combined with Difluocortolone.
Digitoxin	The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mobocertinib.
Digoxin	The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mobocertinib.
Dihydroergotamine	The serum concentration of Dihydroergotamine can be decreased when it is combined with Mobocertinib.
Diltiazem	The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Mobocertinib.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Mobocertinib.
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mobocertinib.
Disopyramide	The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Mobocertinib.
Disulfiram	The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Mobocertinib.
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Mobocertinib.
Dofetilide	The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Mobocertinib.
Dolasetron	The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mobocertinib.
Domperidone	The risk or severity of QTc prolongation can be increased when Domperidone is combined with Mobocertinib.
Doravirine	The metabolism of Mobocertinib can be decreased when combined with Doravirine.
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Mobocertinib.
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Mobocertinib.
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Mobocertinib.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Mobocertinib.
Dronedarone	The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Mobocertinib.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Mobocertinib.
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Mobocertinib.
Dutasteride	The metabolism of Mobocertinib can be decreased when combined with Dutasteride.
Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mobocertinib.
Econazole	The serum concentration of Mobocertinib can be increased when it is combined with Econazole.
Efavirenz	The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mobocertinib.
Elbasvir	The metabolism of Mobocertinib can be decreased when combined with Elbasvir.
Elexacaftor	The metabolism of Mobocertinib can be decreased when combined with Elexacaftor.
Eliglustat	The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Mobocertinib.
Elvitegravir	The serum concentration of Mobocertinib can be increased when it is combined with Elvitegravir.
Emapalumab	The metabolism of Mobocertinib can be increased when combined with Emapalumab.
Emedastine	The risk or severity of QTc prolongation can be increased when Emedastine is combined with Mobocertinib.
Enasidenib	The serum concentration of Enasidenib can be decreased when it is combined with Mobocertinib.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Mobocertinib.
Encorafenib	The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mobocertinib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Mobocertinib.
Entrectinib	The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Mobocertinib.
Enzalutamide	The serum concentration of Mobocertinib can be decreased when it is combined with Enzalutamide.
Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Mobocertinib.
Eplerenone	The metabolism of Mobocertinib can be decreased when combined with Eplerenone.
Erdafitinib	The serum concentration of Erdafitinib can be decreased when it is combined with Mobocertinib.
Ergotamine	The serum concentration of Mobocertinib can be increased when it is combined with Ergotamine.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mobocertinib.
Erlotinib	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Mobocertinib.
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mobocertinib.
Escitalopram	The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Mobocertinib.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mobocertinib.
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Mobocertinib.
Estradiol acetate	The metabolism of Mobocertinib can be decreased when combined with Estradiol acetate.
Estradiol benzoate	The serum concentration of Estradiol benzoate can be decreased when it is combined with Mobocertinib.

Estradiol cypionate	The serum concentration of Estradiol cypionate can be decreased when it is combined with Mobocertinib.
Estradiol dienanthate	The metabolism of Mobocertinib can be decreased when combined with Estradiol dienanthate.
Estradiol valerate	The serum concentration of Estradiol valerate can be decreased when it is combined with Mobocertinib.
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Mobocertinib.
Etanercept	The metabolism of Mobocertinib can be increased when combined with Etanercept.
Ethinylestradiol	The serum concentration of Ethinylestradiol can be decreased when it is combined with Mobocertinib.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Mobocertinib.
Ethynodiol	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mobocertinib.
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Mobocertinib.
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Mobocertinib.
Everolimus	The serum concentration of Everolimus can be decreased when it is combined with Mobocertinib.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Mobocertinib.
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mobocertinib.
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Mobocertinib.
Felodipine	The risk or severity of QTc prolongation can be increased when Felodipine is combined with Mobocertinib.
Fentanyl	The metabolism of Mobocertinib can be decreased when combined with Fentanyl.
Fexinidazole	The risk or severity of adverse effects can be increased when Mobocertinib is combined with Fexinidazole.
Finasteride	The metabolism of Mobocertinib can be decreased when combined with Finasteride.
Flecainide	The risk or severity of QTc prolongation can be increased when Flecainide is combined with Mobocertinib.
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Mobocertinib.
Fluocinonide	The metabolism of Mobocertinib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Mobocertinib can be increased when combined with Fluocortolone.
Fluorouracil	The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mobocertinib.
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mobocertinib.
Flupentixol	The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Mobocertinib.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Mobocertinib.
Flutamide	The metabolism of Mobocertinib can be decreased when combined with Flutamide.
Fluticasone	The metabolism of Mobocertinib can be decreased when combined with Fluticasone.
Fluticasone furoate	The metabolism of Mobocertinib can be decreased when combined with Fluticasone furoate.
Fluticasone	The metabolism of Mobocertinib can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Mobocertinib can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Mobocertinib can be decreased when combined with Fluvoxamine.
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mobocertinib.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Mobocertinib.
Fosnetupitant	The metabolism of Mobocertinib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The serum concentration of Mobocertinib can be decreased when it is combined with Fosphenytoin.
Fusidic acid	The metabolism of Mobocertinib can be decreased when combined with Fusidic acid.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Mobocertinib.
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mobocertinib.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Mobocertinib.
Gefitinib	The metabolism of Mobocertinib can be decreased when combined with Gefitinib.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Mobocertinib.
Gestrinone	The serum concentration of Gestrinone can be decreased when it is combined with Mobocertinib.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mobocertinib.
Glasdegib	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Mobocertinib.
Glyburide	The metabolism of Mobocertinib can be decreased when combined with Glyburide.
Golimumab	The metabolism of Mobocertinib can be increased when combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mobocertinib.
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Mobocertinib.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Mobocertinib.
Halofantrine	The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Mobocertinib.
Haloperidol	The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mobocertinib.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Mobocertinib.
Hydrochlorothiazide	The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Mobocertinib.
Hydrocortisone	The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone.
Hydrocortisone	The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone acetate.
Hydrocortisone	The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone butyrate.
Hydrocortisone	The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone cypionate.
Hydrocortisone	The metabolism of Mobocertinib can be decreased when combined with Hydrocortisone phosphate.
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Mobocertinib.
Hydroxyprogester	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Mobocertinib.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Mobocertinib is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Mobocertinib.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mobocertinib.
Ibrutinib	The metabolism of Mobocertinib can be decreased when combined with Ibrutinib.
Ibutilide	The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Mobocertinib.
Idelalisib	The serum concentration of Idelalisib can be decreased when it is combined with Mobocertinib.
Ifosfamide	The serum concentration of Ifosfamide can be decreased when it is combined with Mobocertinib.
Iloperidone	The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Mobocertinib.
Imatinib	The risk or severity of QTc prolongation can be increased when Imatinib is combined with Mobocertinib.
Imipramine	The risk or severity of QTc prolongation can be increased when Imipramine is combined with Mobocertinib.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mobocertinib.
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mobocertinib.
Indinavir	The serum concentration of Mobocertinib can be increased when it is combined with Indinavir.
Infliximab	The metabolism of Mobocertinib can be increased when combined with Infliximab.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Mobocertinib.
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Mobocertinib.
Isavuconazole	The metabolism of Mobocertinib can be decreased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Mobocertinib can be decreased when combined with Isavuconazonium.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Mobocertinib.
Isoniazid	The metabolism of Mobocertinib can be decreased when combined with Isoniazid.
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Mobocertinib.
Istradefylline	The metabolism of Mobocertinib can be decreased when combined with Istradefylline.
Itraconazole	The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Mobocertinib.
Ivabradine	The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Mobocertinib.
Ivacaftor	The metabolism of Mobocertinib can be decreased when combined with Ivacaftor.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Mobocertinib.
Ixabepilone	The serum concentration of Ixabepilone can be decreased when it is combined with Mobocertinib.
Ixazomib	The serum concentration of Ixazomib can be decreased when it is combined with Mobocertinib.
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Mobocertinib.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Mobocertinib.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Mobocertinib.
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Mobocertinib.
Lefamulin	The risk or severity of QTc prolongation can be increased when Lefamulin is combined with Mobocertinib.
Lemborexant	The metabolism of Mobocertinib can be decreased when combined with Lemborexant.
Lenvatinib	The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Mobocertinib.
Lercanidipine	The metabolism of Mobocertinib can be decreased when combined with Lercanidipine.
Letermovir	The metabolism of Mobocertinib can be decreased when combined with Letermovir.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mobocertinib.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Mobocertinib.

Levamlodipine	The metabolism of Mobocertinib can be decreased when combined with Levamlodipine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Mobocertinib.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Mobocertinib.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mobocertinib.
Levoketoconazole	The risk or severity of QTc prolongation can be increased when Levoketoconazole is combined with Mobocertinib.
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Mobocertinib.
Levosimendan	The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Mobocertinib.
Lidocaine	The metabolism of Mobocertinib can be decreased when combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Mobocertinib.
Linagliptin	The metabolism of Mobocertinib can be decreased when combined with Linagliptin.
Lofexidine	The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Mobocertinib.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Mobocertinib.
Lomitapide	The serum concentration of Lomitapide can be decreased when it is combined with Mobocertinib.
Lonafarnib	The serum concentration of Mobocertinib can be increased when it is combined with Lonafarnib.
Loperamide	The risk or severity of QTc prolongation can be increased when Loperamide is combined with Mobocertinib.
Lopinavir	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Mobocertinib.
Lorlatinib	The metabolism of Mobocertinib can be decreased when combined with Lorlatinib.
Losartan	The risk or severity of QTc prolongation can be increased when Losartan is combined with Mobocertinib.
Lovastatin	The metabolism of Mobocertinib can be decreased when combined with Lovastatin.
Lumacaftor	The serum concentration of Mobocertinib can be decreased when it is combined with Lumacaftor.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Mobocertinib.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Mobocertinib.
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Mobocertinib.
Macimorelin	The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Mobocertinib.
Malathion	The risk or severity of QTc prolongation can be increased when Malathion is combined with Mobocertinib.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Mobocertinib.
Mavacamten	The serum concentration of Mobocertinib can be decreased when it is combined with Mavacamten.
Medroxyprogeste	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mobocertinib.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Mobocertinib.
Megestrol acetate	The serum concentration of Megestrol acetate can be decreased when it is combined with Mobocertinib.
Meprednisone	The metabolism of Mobocertinib can be increased when combined with Meprednisone.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Mobocertinib.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Mobocertinib.
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Mobocertinib.
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Mobocertinib.
Methimazole	The serum concentration of Mobocertinib can be increased when it is combined with Methimazole.
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Mobocertinib.
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Mobocertinib.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mobocertinib.
Methylene blue	The metabolism of Mobocertinib can be decreased when combined with Methylene blue.
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mobocertinib.
Metreleptin	The metabolism of Mobocertinib can be increased when combined with Metreleptin.
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Mobocertinib.
Miconazole	The metabolism of Mobocertinib can be decreased when combined with Miconazole.
Midazolam	The metabolism of Mobocertinib can be decreased when combined with Midazolam.
Midostaurin	The serum concentration of Mobocertinib can be decreased when it is combined with Midostaurin.
Mifepristone	The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Mobocertinib.
Milnacipran	The metabolism of Mobocertinib can be decreased when combined with Milnacipran.
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Mobocertinib.
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Mobocertinib.
Mitotane	The serum concentration of Mobocertinib can be decreased when it is combined with Mitotane.
Mizolastine	The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Mobocertinib.
Modafinil	The metabolism of Mobocertinib can be increased when combined with Modafinil.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Mobocertinib.
Mometasone	The metabolism of Mobocertinib can be increased when combined with Mometasone furoate.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Mobocertinib.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mobocertinib.
Mycophenolate	The metabolism of Mobocertinib can be decreased when combined with Mycophenolate mofetil.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Mobocertinib.
Naloxone	The serum concentration of Mobocertinib can be increased when it is combined with Naloxone.
Nateglinide	The metabolism of Mobocertinib can be decreased when combined with Nateglinide.
Nefazodone	The serum concentration of Mobocertinib can be increased when it is combined with Nefazodone.
Nelfinavir	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Mobocertinib.
Neratinib	The serum concentration of Neratinib can be decreased when it is combined with Mobocertinib.
Netupitant	The metabolism of Mobocertinib can be decreased when combined with Netupitant.
Nevirapine	The metabolism of Mobocertinib can be decreased when combined with Nevirapine.
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Mobocertinib.
Nifedipine	The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Mobocertinib.
Nilotinib	The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Mobocertinib.
Nilvadipine	The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Mobocertinib.
Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Mobocertinib.
Nisoldipine	The metabolism of Mobocertinib can be decreased when combined with Nisoldipine.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Mobocertinib.
Nomegestrol	The serum concentration of Nomegestrol can be decreased when it is combined with Mobocertinib.
Nomegestrol	The serum concentration of Nomegestrol acetate can be decreased when it is combined with Mobocertinib.
Nonoxynol-9	The serum concentration of Nonoxynol-9 can be decreased when it is combined with Mobocertinib.
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Mobocertinib.
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Mobocertinib.
Norethynodrel	The serum concentration of Norethynodrel can be decreased when it is combined with Mobocertinib.
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Mobocertinib.
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Mobocertinib.
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Mobocertinib.
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Mobocertinib.
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mobocertinib.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Mobocertinib.
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Mobocertinib.
Olaparib	The serum concentration of Olaparib can be decreased when it is combined with Mobocertinib.
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Mobocertinib.
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Mobocertinib.
Orphenadrine	The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Mobocertinib.
Osilodrostat	The metabolism of Mobocertinib can be decreased when combined with Osilodrostat.
Osimertinib	The serum concentration of Osimertinib can be decreased when it is combined with Mobocertinib.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mobocertinib.
Oxatomide	The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Mobocertinib.
Oxcarbazepine	The metabolism of Mobocertinib can be increased when combined with Oxcarbazepine.
Oxprenolol	The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Mobocertinib.
Oxybutynin	The metabolism of Mobocertinib can be decreased when combined with Oxybutynin.
Oxycodone	The metabolism of Mobocertinib can be decreased when combined with Oxycodone.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mobocertinib.
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Mobocertinib.

Pacritinib	The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Mobocertinib.
Palbociclib	The serum concentration of Palbociclib can be decreased when it is combined with Mobocertinib.
Paliperidone	The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Mobocertinib.
Panobinostat	The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Mobocertinib.
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mobocertinib.
Paritaprevir	The metabolism of Mobocertinib can be decreased when combined with Paritaprevir.
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Mobocertinib.
Pazopanib	The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Mobocertinib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Mobocertinib.
Pentamidine	The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Mobocertinib.
Pentobarbital	The serum concentration of Mobocertinib can be decreased when it is combined with Pentobarbital.
Perampanel	The metabolism of Mobocertinib can be decreased when combined with Perampanel.
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mobocertinib.
Perhexiline	The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Mobocertinib.
Pexidartinib	The serum concentration of Pexidartinib can be decreased when it is combined with Mobocertinib.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mobocertinib.
Phenobarbital	The serum concentration of Mobocertinib can be decreased when it is combined with Phenobarbital.
Phenprocoumon	The serum concentration of Phenprocoumon can be decreased when it is combined with Mobocertinib.
Phenytoin	The serum concentration of Mobocertinib can be decreased when it is combined with Phenytoin.
Pimozide	The risk or severity of QTc prolongation can be increased when Pimozide is combined with Mobocertinib.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Mobocertinib.
Pitolisant	The risk or severity of QTc prolongation can be increased when Pitolisant is combined with Mobocertinib.
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Mobocertinib.
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Mobocertinib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Mobocertinib.
Posaconazole	The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Mobocertinib.
Pralsetinib	The metabolism of Mobocertinib can be decreased when combined with Pralsetinib.
Praziquantel	The metabolism of Mobocertinib can be decreased when combined with Praziquantel.
Prednisolone	The metabolism of Mobocertinib can be increased when combined with Prednisolone phosphate.
Prednisone	The metabolism of Mobocertinib can be increased when combined with Prednisone acetate.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Mobocertinib.
Prenylamine	The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Mobocertinib.
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Mobocertinib.
Primidone	The serum concentration of Mobocertinib can be decreased when it is combined with Primidone.
Probucol	The risk or severity of QTc prolongation can be increased when Probucol is combined with Mobocertinib.
Procainamide	The risk or severity of QTc prolongation can be increased when Procainamide is combined with Mobocertinib.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Mobocertinib.
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Mobocertinib.
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Mobocertinib.
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Mobocertinib.
Propafenone	The risk or severity of QTc prolongation can be increased when Propafenone is combined with Mobocertinib.
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Mobocertinib.
Propranolol	The risk or severity of QTc prolongation can be increased when Propranolol is combined with Mobocertinib.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Mobocertinib.
Quetiapine	The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Mobocertinib.
Quinidine	The risk or severity of QTc prolongation can be increased when Quinidine is combined with Mobocertinib.
Quinine	The risk or severity of QTc prolongation can be increased when Quinine is combined with Mobocertinib.
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Mobocertinib.
Regorafenib	The serum concentration of Regorafenib can be decreased when it is combined with Mobocertinib.
Relugolix	The metabolism of Mobocertinib can be decreased when combined with Relugolix.
Reserpine	The metabolism of Mobocertinib can be increased when combined with Reserpine.
Ribociclib	The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Mobocertinib.
Rifampicin	The serum concentration of Mobocertinib can be decreased when it is combined with Rifampicin.
Rifamycin	The serum concentration of Mobocertinib can be decreased when it is combined with Rifamycin.
Rifapentine	The serum concentration of Mobocertinib can be decreased when it is combined with Rifapentine.
Rilonacept	The metabolism of Mobocertinib can be increased when combined with Rilonacept.
Rilpivirine	The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mobocertinib.
Rimexolone	The serum concentration of Mobocertinib can be decreased when it is combined with Rimexolone.
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Mobocertinib.
Ritonavir	The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Mobocertinib.
Rivaroxaban	The metabolism of Mobocertinib can be decreased when combined with Rivaroxaban.
Romidepsin	The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Mobocertinib.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Mobocertinib.
Rosuvastatin	The metabolism of Mobocertinib can be decreased when combined with Rosuvastatin.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Mobocertinib.
Rucaparib	The metabolism of Mobocertinib can be decreased when combined with Rucaparib.
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Mobocertinib.
Ruxolitinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Mobocertinib.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.
Salmeterol	The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mobocertinib.
Saquinavir	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Mobocertinib.
Satralizumab	The serum concentration of Mobocertinib can be decreased when it is combined with Satralizumab.
Saxagliptin	The metabolism of Mobocertinib can be decreased when combined with Saxagliptin.
Secukinumab	The metabolism of Mobocertinib can be increased when combined with Secukinumab.
Segesterone	The serum concentration of Segesterone acetate can be decreased when it is combined with Mobocertinib.
Selpercatinib	The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Mobocertinib.
Selumetinib	The metabolism of Mobocertinib can be decreased when combined with Selumetinib.
Sertindole	The risk or severity of QTc prolongation can be increased when Sertindole is combined with Mobocertinib.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Mobocertinib.
Sildenafil	The metabolism of Mobocertinib can be decreased when combined with Sildenafil.
Siltuximab	The metabolism of Mobocertinib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Mobocertinib can be decreased when combined with Simeprevir.
Simvastatin	The metabolism of Mobocertinib can be decreased when combined with Simvastatin.
Siponimod	The serum concentration of Siponimod can be decreased when it is combined with Mobocertinib.
Sirolimus	The serum concentration of Sirolimus can be decreased when it is combined with Mobocertinib.
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Mobocertinib.
Somatrogon	The metabolism of Mobocertinib can be increased when combined with Somatrogon.
Sonidegib	The serum concentration of Sonidegib can be decreased when it is combined with Mobocertinib.
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Mobocertinib.
Sotalol	The risk or severity of QTc prolongation can be increased when Sotalol is combined with Mobocertinib.
Sotorasib	The serum concentration of Mobocertinib can be decreased when it is combined with Sotorasib.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Mobocertinib.
St. John’s Wort	The serum concentration of Mobocertinib can be decreased when it is combined with St. John’s Wort.
Stiripentol	The serum concentration of Mobocertinib can be increased when it is combined with Stiripentol.
Sulfamethoxazole	The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mobocertinib.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Mobocertinib.
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Mobocertinib.
Sultopride	The risk or severity of QTc prolongation can be increased when Sultopride is combined with Mobocertinib.
Sunitinib	The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mobocertinib.
Tacrolimus	The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Mobocertinib.

Tadalafil	The metabolism of Mobocertinib can be decreased when combined with Tadalafil.
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Mobocertinib.
Tegafur	The serum concentration of Tegafur can be decreased when it is combined with Mobocertinib.
Telaprevir	The serum concentration of Mobocertinib can be increased when it is combined with Telaprevir.
Telavancin	The risk or severity of QTc prolongation can be increased when Telavancin is combined with Mobocertinib.
Telithromycin	The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Mobocertinib.
Telotristat ethyl	The serum concentration of Mobocertinib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Mobocertinib.
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Mobocertinib.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mobocertinib.
Terfenadine	The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Mobocertinib.
Terlipressin	The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Mobocertinib.
Testosterone	The metabolism of Mobocertinib can be decreased when combined with Testosterone.
Testosterone	The metabolism of Mobocertinib can be decreased when combined with Testosterone cypionate.
Testosterone	The serum concentration of Testosterone enanthate can be decreased when it is combined with Mobocertinib.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Mobocertinib.
Tezacaftor	The metabolism of Mobocertinib can be decreased when combined with Tezacaftor.
Thalidomide	The metabolism of Mobocertinib can be increased when combined with Thalidomide.
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Mobocertinib.
Thioridazine	The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Mobocertinib.
Thiotepa	The serum concentration of Thiotepa can be decreased when it is combined with Mobocertinib.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mobocertinib.
Ticagrelor	The metabolism of Mobocertinib can be decreased when combined with Ticagrelor.
Timolol	The risk or severity of QTc prolongation can be increased when Timolol is combined with Mobocertinib.
Tipranavir	The serum concentration of Mobocertinib can be increased when it is combined with Tipranavir.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Mobocertinib.
Tocilizumab	The metabolism of Mobocertinib can be increased when combined with Tocilizumab.
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Mobocertinib.
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Mobocertinib.
Toremifene	The risk or severity of QTc prolongation can be increased when Toremifene is combined with Mobocertinib.
Trabectedin	The serum concentration of Trabectedin can be decreased when it is combined with Mobocertinib.
Trastuzumab	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Mobocertinib.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Mobocertinib.
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Mobocertinib.
Tretinoin	The metabolism of Mobocertinib can be decreased when combined with Tretinoin.
Triamcinolone	The metabolism of Mobocertinib can be increased when combined with Triamcinolone.
Triazolam	The metabolism of Mobocertinib can be decreased when combined with Triazolam.
Triclabendazole	The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Mobocertinib.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Mobocertinib.
Trimethadione	The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Mobocertinib.
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Mobocertinib.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Mobocertinib.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mobocertinib.
Troglitazone	The metabolism of Mobocertinib can be decreased when combined with Troglitazone.
Troleandomycin	The serum concentration of Mobocertinib can be increased when it is combined with Troleandomycin.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Mobocertinib.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Mobocertinib.
Udenafil	The metabolism of Mobocertinib can be decreased when combined with Udenafil.
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Mobocertinib.
Valbenazine	The metabolism of Mobocertinib can be decreased when combined with Valbenazine.
Valproic acid	The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Mobocertinib.
Vandetanib	The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Mobocertinib.
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Mobocertinib.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mobocertinib.
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Mobocertinib.
Verapamil	The metabolism of Mobocertinib can be decreased when combined with Verapamil.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Mobocertinib.
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Mobocertinib.
Viloxazine	The metabolism of Mobocertinib can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Mobocertinib.
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Mobocertinib.
Vindesine	The serum concentration of Vindesine can be decreased when it is combined with Mobocertinib.
Vinflunine	The serum concentration of Vinflunine can be decreased when it is combined with Mobocertinib.
Vinorelbine	The serum concentration of Vinorelbine can be decreased when it is combined with Mobocertinib.
Vonoprazan	The metabolism of Mobocertinib can be decreased when combined with Vonoprazan.
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Mobocertinib.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Mobocertinib.
Vortioxetine	The metabolism of Mobocertinib can be decreased when combined with Vortioxetine.
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Mobocertinib.
Zaleplon	The metabolism of Mobocertinib can be decreased when combined with Zaleplon.
Zanubrutinib	The serum concentration of Zanubrutinib can be decreased when it is combined with Mobocertinib.
Zimelidine	The metabolism of Mobocertinib can be decreased when combined with Zimelidine.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Mobocertinib.
Zonisamide	The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Mobocertinib.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Mobocertinib.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], EXKIVITY can cause fetal harm when administered to a pregnant woman. There are no available data on EXKIVITY use in pregnant women. Oral administration of mobocertinib to pregnant rats during the period of organogenesis resulted in embryolethality (embryo-fetal death) and maternal toxicity at plasma exposures approximately 1.7 times the human exposure based on AUC at the 160 mg once daily clinical dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage
in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of mobocertinib or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with EXKIVITY and for 1 week after the last dose.

How should this medicine be used?

Mobocertinib comes as a capsule to take by mouth. It is usually taken once daily with or without food. The length of your treatment depends on how well this medication works for you, and the side effects that you experience. Take mobocertinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mobocertinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, crush, or dissolve them.

If you vomit after taking mobocertinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose, or interrupt or discontinue your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take mobocertinib even if you feel well. Do not stop taking mobocertinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking mobocertinib,

• tell your doctor and pharmacist if you are allergic to mobocertinib, any other medications, or any of the ingredients in mobocertinib capsules. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: angiotensin-converting enzyme (ACE) inhibitors such as benazepril (Lotensin, in Lotrel), captopril, enalapril (Epaned, Vasotec, in Vaseretic), fosinopril, lisinopril (Prinivil, Qbrelis, Zestril, in Zestoretic), moexipril, perindopril, (in Prestalia), quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril; angiotensin receptor blockers (ARBs) such as azilsartan (Edarbi, in Edarbyclor), candesartan (Atacand, in Atacand HCT), eprosartan (Teveten), irbesartan (Avapro, in Avalide), losartan (Cozaar, in Hyzaar), and valsartan (Diovan, in Diovan HCT, in Exforge, others); diuretics (‘water pills’); efavirenz (Sustiva, in Atripla, in Symfi); hormonal contraceptives (birth control pills, patches, rings, implants, or injections); midazolam; rifampin (Rifadin, Rimactane); and sulfasalazine (Azulfidine). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with mobocertinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
• tell your doctor if you have or have ever had asthma, emphysema, or other breathing problems (other than lung cancer); or kidney or liver disease.
• tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for 1 month after your final dose. Talk to your doctor about which methods you should use; hormonal contraceptives (birth control pills, patches, implants, rings, or injections) may not work well in women who are taking mobocertinib. If you are a male, you and your partner should use birth control during your treatment with mobocertinib and for 7 days after your final dose. If you or your partner become pregnant while taking mobocertinib, call your doctor immediately. Mobocertinib may harm the fetus.
• tell your doctor if you are breastfeeding. You should not breastfeed while you are taking mobocertinib and for 7 days after the final dose.
• you should know that mobocertinib often causes diarrhea, which can be severe. Call your doctor if you have diarrhea while taking mobocertinib. Your doctor may tell you to drink plenty of liquids, make changes in your diet, and take medication to control the diarrhea and prevent dehydration (loss of too much water from your body). Call your doctor immediately if you experience any of the following symptoms of dehydration: extreme thirst, dry mouth and/or skin, decreased urination, sunken eyes, or fast heartbeat.

References

Show More